Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
June, 2026
June 2026
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Ney Carter Borges: FAVOR III China Demonstrates a 37% Reduction in Myocardial Infarction with QFR Guidance
Ney Carter Borges/LinkedIn
Jun 27, 2026, 12:00

Ney Carter Borges: FAVOR III China Demonstrates a 37% Reduction in Myocardial Infarction with QFR Guidance

Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared on LinkedIn about a recent article by Han Zhang et al, published in JACC, adding:

”QFR-Guided PCI Improves 5-Year Outcomes: The FAVOR III China Trial

The FAVOR III China trial provides the longest follow-up to date evaluating an angiography-derived physiological strategy for guiding percutaneous coronary intervention (PCI).

In this multicenter, randomized study involving 3,825 patients with intermediate coronary stenoses, participants were assigned to PCI guided either by Quantitative Flow Ratio (QFR) or by conventional angiography alone.

After 5 years, QFR guidance significantly reduced the incidence of major adverse cardiovascular events (MACE) compared with angiography-guided PCI (17.5% vs 21.1%; HR 0.80; 95% CI 0.69–0.92; p=0.002).

This benefit was primarily driven by a 37% reduction in myocardial infarction (5.8% vs 9.0%; HR 0.63; p<0.0001) and a 22% reduction in ischemia-driven repeat revascularization (9.6% vs 12.0%; HR 0.78; p=0.02).

Overall mortality was similar between groups, confirming that the physiological strategy improves ischemic outcomes without affecting long-term survival.

An important finding is that QFR-guided PCI resulted in fewer procedures and fewer implanted stents, while achieving greater functional completeness of revascularization.

By identifying lesions that truly produced ischemia, QFR avoided unnecessary interventions without compromising safety.

Landmark analysis demonstrated that most of the clinical advantage occurred during the first two years after PCI.

From years 2 to 5, event rates became similar, suggesting that the principal benefit of physiological guidance is the optimization of the initial revascularization strategy rather than continuous divergence over time.

Clinical message: QFR offers a practical, wire-free physiological alternative to FFR, allowing more precise lesion selection while reducing procedural complexity.

These 5-year results reinforce QFR as an effective strategy to improve long-term clinical outcomes, decrease unnecessary stenting, and reduce myocardial infarction and repeat revascularization in patients undergoing PCI.”

Title: Angiographic Quantitative Flow Ratio-Guided Coronary Intervention: 5-Year Follow-Up From the FAVOR III China Randomized Trial

Authors: Han Zhang, Changdong Guan, Zening Jin, Bo Yu, Guosheng Fu, Yujie Zhou, Jian’an Wang, Yundai Chen, Jun Pu, Lianglong Chen, Xinkai Qu, Junqing Yang, Xuebo Liu, Lijun Guo, Chengxing Shen, Yaojun Zhang, Qi Zhang, Hongwei Pan, Jian Liu, Yanyan Zhao, Yang Wang, Kefei Dou, Ajay J. Kirtane, Yongjian Wu, Weixian Yang, Shubin Qiao, Shengxian Tu, Gregg W. Stone, Lei Song

Ney Carter Borges: FAVOR III China Demonstrates a 37% Reduction in Myocardial Infarction with QFR Guidance

Stay updated on all scientific advances with Hemostasis Today.

Ajay J. Kirtane Bo Yu Changdong Guan Chengxing Shen China FAVOR III Gregg W. Stone Guosheng Fu Han Zhang Health Hematology Hemostasis Hemostasis News Hemostasis Today Hongwei Pan Jian Liu Jian'an Wang Jun Pu Junqing Yang Kefei Dou Lei Song Lianglong Chen Lijun Guo Medicine Ney Carter Borges PCI Qi Zhang Shengxian Tu Shubin Qiao thrombosis Weixian Yang Xinkai Qu Xuebo Liu Yang Wang Yanyan Zhao Yaojun Zhang Yongjian Wu Yujie Zhou Yundai Chen Zening Jin
NewsFeed